Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors

被引:34
作者
Jerman, JC
Gray, J
Brough, SJ
Ooi, L
Owen, D
Davis, JB
Smart, D
机构
[1] GlaxoSmithKline, Dept Discovery Res, Harlow, Essex, England
[2] GlaxoSmithKline, Dept Neurol, Harlow, Essex, England
关键词
analgesics non-opioid; anandamide; spinal cord; dorsal root ganglion; equipment; flurometric imaging plate reader; receptors; cannabinoid; vanilloid;
D O I
10.1093/bja/aef281
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background. Anandamide, an endogenous lipid, activates both cannabinoid (CB1) and vanilloid (VR1) receptors, both of which are co-expressed in rat dorsal root ganglion (DRG) cells. Activation of either receptor results in analgesia but the relative contribution of CB1 and VR1 in anandamide-induced analgesia remains controversial. Here we compare the in vitro pharmacology of recombinant and endogenous VR1 receptors using calcium imaging, in clonal and DRG cells, respectively. We also consider the contribution of CB1 and VR1 receptors to anandamide-induced analgesia. Methods. Using a Flurometric Imaging Plate Reader (FLIPR(TM)), calcium imaging has been used to study the effects of several vanilloid and cannabinoid ligands in rat VR1-transfected HEK293 (rVR1-HEK) cells and in DRG cells. The effect of pre-exposure of several vanilloid and cannabinoids has also been compared in DRG cells. Results. The VR1 agonists capsaicin, olvanil, (N-(4-hydroxyphenyl-arachinoylamide) (AM404) and anandamide caused a concentration-dependent increase in intracellular calcium concentration ([Ca2+](i)), with similar temporal profiles in both rVR1-HEK and DRG cells, and potency (pEC(50)) values of 8.25 (sem 0.11), 8.37 (0.04), 6.96 (0.06), 5.85 (0.01) and 7.45 (0.10), 7.55 (0.07), 6.10 (0.13), approximately 5.5, respectively. These responses were inhibited by the VR1 antagonist capsazepine (1 muM). In contrast, application of synthetic cannabinoid antagonists failed to inhibit the anandamide-induced increase in [Ca2+](i). Reapplication of VR1 agonists significantly inhibited a subsequent challenge to either capsaicin or anandamide in either cell type, whilst pre-exposure to cannabinoid agonists were without effect. Conclusion. Here we provide evidence that the pharmacology of recombinant rVR1 receptors is similar to those endogenously expressed in DRG cells. Moreover, we have shown that VR1, but not CB1, receptors are involved in anandamide-induced responses in dorsal root primary neurones in vitro. Therefore, the analgesic properties of anandamide are likely to be mediated, at least in part, by VR1 activation in DRG cells in vivo.
引用
收藏
页码:882 / 887
页数:6
相关论文
共 25 条
[1]  
Adams IB, 1998, J PHARMACOL EXP THER, V284, P1209
[2]   Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons [J].
Ahluwalia, J ;
Urban, L ;
Capogna, M ;
Bevan, S ;
Nagy, I .
NEUROSCIENCE, 2000, 100 (04) :685-688
[3]   Nonlinear regression using spreadsheets [J].
Bowen, WP ;
Jerman, JC .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (12) :413-417
[4]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[5]  
DEVANE WA, 1988, MOL PHARMACOL, V34, P605
[6]   ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR [J].
DEVANE, WA ;
HANUS, L ;
BREUER, A ;
PERTWEE, RG ;
STEVENSON, LA ;
GRIFFIN, G ;
GIBSON, D ;
MANDELBAUM, A ;
ETINGER, A ;
MECHOULAM, R .
SCIENCE, 1992, 258 (5090) :1946-1949
[7]   Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice:: Evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain [J].
Di Marzo, V ;
Breivogel, CS ;
Tao, Q ;
Bridgen, DT ;
Razdan, RK ;
Zimmer, AM ;
Zimmer, A ;
Martin, BR .
JOURNAL OF NEUROCHEMISTRY, 2000, 75 (06) :2434-2444
[8]  
Di Marzo V, 2000, CURR PHARM DESIGN, V6, P1361
[9]  
Huffman JW, 1996, CURR MED CHEM, V3, P101
[10]   Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology [J].
Jerman, JC ;
Brough, SJ ;
Prinjha, R ;
Harries, MH ;
Davis, JB ;
Smart, D .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (04) :916-922